natgillin/translations-raw huggingface dataset:
Do this by: wearing protective clothing which also covers your head, neck, arms and legs using a sunscreen with a high protection factor.
• uporabljate zaščitna oblačila, ki pokrijejo tudi vašo glavo, vrat, roke in noge,
Patients on CellCept who develop recurrent infections should have their serum immunoglobulins measured.
Bolnikom, ki jemljejo zdravilo CellCept in se jim okužbe ponavljajo, je treba določiti raven imunoglobulinov v serumu.
Adverse reactions attributable to peripheral venous infusion were phlebitis and thrombosis, both observed at 4% in patients treated with CellCept 500 mg powder for concentrate for solution for infusion.
Neželena učinka, ki ju lahko pripišemo periferni venski infuziji, sta bila flebitis in tromboza, ki so ju opazili pri 4 % bolnikov, zdravljenih z zdravilom CellCept 500 mg prašek za koncentrat za raztopino za infundiranje.
METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous infusion only Reconstitute and dilute before use Read the package leaflet before use
POSTOPEK IN POT(I) UPORABE ZDRAVILA Samo za intravensko infuzijo Pred uporabo rekonstituirajte in razredčite Pred uporabo preberite priloženo navodilo
Some of the more usual problems are diarrhoea, fewer white cells or red cells in your blood, infection and vomiting.
Običajne težave Pogostejše težave so driska, zmanjšano število belih ali rdečih krvničk v krvi, okužbe in bruhanje.
Take off the child safety bottle cap and push the bottle adapter into the neck of the bottle.
Odstranite za otroke varno zaporko in v vrat steklenice potisnite nastavek za steklenico.
The first dose is given to you as soon as possible after the transplant operation.
• Prvi odmerek boste prejeli čimprej po presaditvenem posegu.
These are insufficient to make dosage recommendations, and therefore use in this age group is not recommended.
Ti so nezadostni za navodila o priporočenem odmerjanju, zato uporaba zdravila CellCept v tej starostni skupini ni priporočljiva.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Ime in naslov proizvajalca, odgovornega za sproščanje serij
Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, CellCept tablets should not be crushed.
Ker ima mofetilmikofenolat dokazane teratogene učinke pri podganah in kuncih, se CellCept tablet ne ne sme zdrobiti.
Musculoskeletal pain such as myalgia, and neck and back pain were also very commonly reported.
Zelo pogosto so poročali tudi o mišično-skeletnih bolečinah, kot so mialgija ter bolečine v vratu in hrbtu.
Cytopenias, including leucopenia, anemia, thrombocytopenia and pancytopenia, are known risks associated with mycophenolate mofetil and may lead or contribute to the occurrence of infections and hemorrhages (see section 4.4).
Citopenije, vključno z levkopenijo, anemijo, trombocitopenijo in pancitopenijo, so znana tveganja, povezana z mofetilmikofenolatom, in lahko povzročijo ali prispevajo k nastanku okužb in krvavitev (glejte poglavje 4.4).
Renal transplant n = 991
Presaditev ledvice n = 991
Dose adjustment of CellCept does not appear to be necessary.
Prilagajanje odmerkov zdravila CellCept ni potrebno.
• Take 4 capsules in the morning and then 4 capsules in the evening.
• Vzemite 4 kapsule zjutraj in 4 kapsule zvečer.
Take care not to let the made-up medicine get into your eyes.
Bodite previdni, da pripravljeno zdravilo ne pride v oči.
There are no data on CellCept with phosphate binders other than sevelamer.
Ni podatkov o dajanju zdravila CellCept z drugimi vezalci fosfatov, razen sevelamerjem.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Oral CellCept should be initiated within 5 days following transplantation.
Peroralno dajanje zdravila CellCept je treba uvesti v 5 dneh po presaditvi.
No substantial alteration of MPA pharmacokinetics is anticipated and CellCept dose adjustment is not required.
Znatnih sprememb v farmakokinetiki mikofenolne kisline ni pričakovati, zato prilagajanje odmerkov zdravila CellCept ni potrebno.
Hypersensitivity reactions, including angioneurotic oedema and anaphylactic reaction have been reported.
Preobčutljivost Poročali so o preobčutljivostnih reakcijah, vključno z angionevrotskim edemom in anafilaktično reakcijo.
Safety and efficacy of CellCept for infusion in paediatric patients have not been established.
Varnost in učinkovitost infuzije zdravila CellCept pri otrocih niso raziskovali.
For instruction on reconstitution of the medicinal product before administration, see section 6.6.
Za navodila o rekonstituciji zdravila pred njegovo uporabo glejte poglavje 6.6.
The parent substance mycophenolate mofetil can be measured systemically during intravenous infusion.
Prvotno učinkovino mofetilmikofenolat lahko sistematično merimo med intravenskim infundiranjem.
• Your womb (uterus) has been removed by surgery (hysterectomy)
• so vam z operacijo odstranili maternico (uterus) - histerektomija;
OTHER SPECIAL WARNING(S), IF NECESSARY Do not breathe the powder before constitution or allow it to touch your skin Avoid skin contact with the reconstituted suspension
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Praška pred pripravo suspenzije ne vdihavajte Izogibajte se stiku praška s kožo Izogibajte se neposrednemu stiku pripravljene suspenzije s kožo
Manufacturing Authorisation holder responsible for batch release: Roche Pharma AG, Emil-Barell-Str. 1, 79639 Grenzach Wyhlen, Germany.
Proizvajalec, odgovoren za sproščanje serije Roche Pharma AG, Emil-Barell-Str. 1, 79639 Grenzach-Wyhlen, Nemčija
• Based on literature reports, malformations occurred in 23 to 27% of live births in women exposed to mycophenolate mofetil during pregnancy (compared to 2 to 3 % of live births in the overall population and approximately 4 to 5% of live births in solid organ transplant recipients treated with immunosuppressants other than mycophenolate mofetil).
• V literaturnih poročilih so se malformacije pojavljale pri 23 do 27 % živorojenih otrok bolnic, ki so bile med nosečnostjo izpostavljene mofetilmikofenolatu, (v primerjavi z 2 do 3 % pri živorojenih otrocih v celokupni populaciji ter približno 4 do 5 % pri živorojenih otrocih bolnic s presajenim solidnim organom, zdravljenih z drugimi imunosupresivi razen mofetilmikofenolata).
If the infusion solution is not prepared immediately prior to administration, the commencement of administration of the infusion solution should be within 3 hours from reconstitution and dilution of the medicinal product.
Če raztopine za infundiranje ne pripravite takoj pred dajanjem, mora biti začetek dajanja infuzije v 3 urah po rekonstituciji in razredčitvi zdravila.
Heart and blood vessel problems such as: change in blood pressure, accelerated heartbeat, widening of blood vessels.
Težave s srcem in krvnimi žilami, kot so: • spremembe krvnega tlaka, pospešen srčni utrip, razširitev krvnih žil.
• CellCept tablets are lavender coloured and caplet shaped.
• CellCept tablete so svetlo vijoličaste barve in ovalne oblike.
They have “CellCept 250” printed in black on the capsule cap and “Roche” printed in black on the capsule body.
Natisnjen imajo črni napis “CellCept 250” na glavi kapsule in “Roche” na telesu kapsule.
Oral CellCept should be initiated within 72 hours following transplantation.
Peroralno dajanje zdravila CellCept je treba uvesti v 72 urah po presaditvi.
Male patients of reproductive potential should be made aware of and discuss with a qualified health-care professional the potential risks of fathering a child.
Bolniki, ki lahko spočnejo otroka, se morajo zavedati možnih tveganj spočetja med zdravljenjem in se o njih pogovoriti z usposobljenim zdravstvenim delavcem.
Capsules, hard.
trda kapsula
CellCept IV solution should never be administered by rapid or bolus intravenous injection.
Intravenske raztopine zdravila CellCept nikoli ne smemo dati kot hitro ali bolusno intravensko injekcijo.
The risk/benefit ratio of mycophenolate mofetil in combination with sirolimus has not been established (see also section 4.5).
Razmerja med tveganjem in koristnostjo mofetilmikofenolata v kombinaciji s sirolimusom niso raziskali (glejte tudi poglavje 4.5).
Based on the results of a single dose administration study of recommended doses of oral mycophenolate and IV ganciclovir and the known effects of renal impairment on the pharmacokinetics of CellCept (see section 4.2) and ganciclovir, it is anticipated that co-administration of these agents (which compete for mechanisms of renal tubular secretion) will result in increases in MPAG and ganciclovir concentration.
Na podlagi rezultatov študije enkratnega odmerjanja priporočenih odmerkov peroralne oblike mofetilmikofenolata in intravenske oblike ganciklovirja in znanih učinkov ledvične okvare na farmakokinetiko zdravila CellCept (glejte poglavje 4.2) in ganciklovirja, je pričakovati, da bo sočasno dajanje obeh učinkovin, ki tekmujeta v mehanizmih renalne tubularne sekrecije, povzročilo povečanje koncentracij mikofenolglukuronida in ganciklovirja.
Gently shake the vial to dissolve the medicinal product yielding a slightly yellow solution.
Vialo nežno pretresite, da se učinkovina raztopi, da nastane rahlo rumena raztopina.
If this happens, wash the area thoroughly with soap and water.
Če se to zgodi, površino temeljito sperite z milom in vodo.
PVC/aluminium foil blister strips
Pretisni omoti iz PVC/aluminijske folije
It is recommended that CellCept should not be administered concomitantly with azathioprine because such concomitant administration has not been studied.
Ne priporočamo sočasnega dajanja zdravila CellCept in azatioprina, ker kombiniranega jemanja teh zdravil niso proučevali.
CellCept is contraindicated during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection.
Zdravilo CellCept je med nosečnostjo kontraindicirano, razen če za preprečitev zavrnitve presadka ni na voljo primernega alternativnega zdravljenja.
When you are able to swallow, you will be given this medicine by mouth.
• Ko boste lahko požirali, boste zdravilo prejeli peroralno.
CellCept 1 g/5 ml powder for oral suspension contains aspartame.
Zdravilo CellCept 1 g/5 ml prašek za peroralno suspenzijo vsebuje aspartam.
As a result of enterohepatic recirculation, secondary increases in plasma MPA concentration are usually observed at approximately 6 - 12 hours post-dose.
Zaradi enterohepatičnega ponovnega obtoka se plazemske koncentracije mikofenolne kisline 6 do 12 ur po odmerku ponovno zvečajo.
Caution is therefore recommended when administering these drugs concomitantly with CellCept.
Zato je pri sočasni uporabi teh zdravil z zdravilom CellCept potrebna previdnost.
In hepatic transplant patients initiated on CellCept and tacrolimus, the AUC and Cmax of MPA, the active metabolite of CellCept, were not significantly affected by co-administration with tacrolimus.
Pri bolnikih z jetrnim presadkom, pri katerih so uvedli zdravilo CellCept in takrolimus, sprememba AUC in Cmax mikofenolne kisline, aktivnega presnovka zdravila CellCept, zaradi sočasnega dajanja takrolimusa ni bila pomembna.
There have been published reports of bronchiectasis in adults and children who received CellCept in combination with other immunosuppressants.
Objavljeni so bili primeri bronhiektazije pri odraslih in otrocih, ki so prejeli zdravilo CellCept v kombinaciji z drugimi imunosupresivi.
CellCept 500 mg powder for concentrate for solution for infusion does not contain an antibacterial preservative; therefore, reconstitution and dilution of the product must be performed under aseptic conditions.
Zdravilo CellCept 500 mg prašek za koncentrat za raztopino za infundiranje ne vsebuje antibakterijskih konzervansov, zato morata rekonstitucija in razredčevanje zdravila potekati pod aseptičnimi pogoji.
Such infections include latent viral reactivation, such as hepatitis B or hepatitis C reactivation and infections caused by polyomaviruses (BK virus associated nephropathy, JC virus associated progressive multifocal leukoencephalopathy PML) .
Take okužbe vključujejo latentno virusno reaktivacijo, kot je reaktivacija virusa hepatitisa B ali hepatitisa C in okužbe, povzročene s poliomavirusi (nefropatijo, povezano z virusom BK, progresivno multifokalno levkoencefalopatijo (PML), povezano z virusom JC).
Wearing disposable gloves is recommended during reconstitution and when wiping the outer surface of the bottle/cap and the table after reconstitution.
Med rekonstitucijo in ob brisanju zunanje površine steklenice/zamaška in mize po rekonstituciji je priporočljivo nositi rokavice za enkratno uporabo.
CellCept capsules: oblong, blue/brown, branded with black "CellCept 250" on the capsule cap and "Roche" name on the capsule body.
CellCept kapsule: ovalne oblike, modro-rjave barve, s črnim napisom “CellCept 250” na glavi kapsule in imenom “Roche” na telesu kapsule.
Take the dispenser and push the plunger completely down toward the tip of the dispenser.
Vzemite razdelilnik in potisnite bat popolnoma do konca proti vrhu razdelilnika.
All patients treated with immunosuppressants are at increased risk of bacterial, viral and fungal infections (some of which may lead to a fatal outcome), including those caused by opportunistic agents and latent viral reactivation.
Pri vseh bolnikih, zdravljenih z imunosupresivi, je povečana nevarnost bakterijskih, virusnih in glivičnih okužb (nekatere od teh imajo lahko smrten izid, ), vključno s tistimi, ki jih povzročajo oportunistični agensi in latentna virusna reaktivacija.
If you have any further questions on the use of this product, ask your doctor or nurse.
Če imate dodatna vprašanja o uporabi tega zdravila, se posvetujte z zdravnikom ali medicinsko sestro.
Infections and infestations Bacterial infections
Infekcijske in parazitske bolezni bakterijske okužbe glivične okužbe protozojske okužbe virusne okužbe
Due to the large differences observed in the frequency of certain ADRs across the different transplant indications, the frequency is presented separately for renal and hepatic transplant patients.
Zaradi velikih razlik v pogostnosti nekaterih neželenih učinkov pri uporabi za različne indikacije je pogostnost prikazana ločeno za bolnike z ledvičnim in jetrnim presadkom.
Of these, 991 were included in the three renal studies and 277 were included in one hepatic study.
Od teh je bilo 991 bolnikov vključenih v tri študije preprečevanja zavrnitve ledvičnega presadka in 277 v študijo preprečevanja zavrnitve jetrnega presadka.
Therefore, CellCept is contraindicated in pregnancy unless there are no suitable alternative treatments to prevent transplant rejection.
Zato je zdravilo CellCept med nosečnostjo kontraindicirano, razen če za preprečitev zavrnitve presadka ni na voljo primernih alternativnih zdravljenj.
Reconstituted solution and the diluted solution: store between 15°C and 30°C.
• Rekonstituirano raztopino in razredčeno raztopino: shranjujte med 15 °C in 30 °C.
Endoscopic investigation of patients with CellCept-related diarrhea have revealed isolated cases of intestinal villous atrophy (see section 4.4).
Endoskopska preiskava bolnikov, pri katerih se je pojavila driska, povezana z zdravilom CellCept, je pokazala posamezne primere atrofije črevesnih resic (glejte poglavje 4.4).
Hepatic transplant n = 277
Presaditev jeter n = 277
CellCept 500 mg film-coated tablets: 1 carton contains 50 tablets (in blister packs of 10)
CellCept 500 mg filmsko obložene tablete: 1 škatla s 50 tabletami (v pretisnih omotih po 10 tablet) skupno pakiranje s 150 (3 škatle po 50) tabletami
Taking food and drink has no effect on your treatment with CellCept.
Zdravilo CellCept skupaj s hrano in pijačo Jemanje skupaj s hrano in pijačo nima učinka na zdravljenje z zdravilom CellCept.
• Cellcept is provided in a 20 mL type I clear glass vial with a grey butyl rubber stopper and aluminium seal with a plastic flip-off cap.
• Zdravilo CellCept je na voljo v 20 ml viali iz bistrega stekla tipa I s sivim zamaškom iz butilne gume, hermetično zaprte z aluminijastim pokrovom s plastično zaporko, ki se odstrani.
No pharmacokinetic data are available during hepatic transplant rejection.
Podatkov o farmakokinetiki pri zavrnitvi jetrnega presadka ni.
20 mL type I clear glass vials with grey butyl rubber stopper and aluminium seals with plastic flip-off caps.
20 ml viale iz bistrega stekla tipa I s sivim zamaškom iz butilne gume, hermetično zaprte z aluminijastim pokrovom s plastično zaporko, ki se odstrani.
AcMPAG is pharmacologically active and is suspected to be responsible for some of MMF´s side effects (diarrhoea, leucopenia).
Ta je farmakološko aktiven in verjetno odgovoren za nekaj neželenih učinkov mofetilmikofenolata (driska, levkopenija).
Before starting CellCept treatment, women of childbearing potential should have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL in order to exclude unintended exposure of the embryo to mycophenolate.
Da izključimo nenamerno izpostavljenost zarodka mofetilmikofenolatu, morajo bolnice v rodni dobi pred začetkom zdravljenja z zdravilom CellCept opraviti dva serumska ali urinska testa nosečnosti z občutljivostjo najmanj 25 mi.e./ml, ki morata biti negativna.
In patients with delayed renal graft function post-transplant, mean MPA AUC0-12h was comparable to that seen in post-transplant patients without delayed graft function.
Pri bolnikih z zapoznelim delovanjem ledvičnega presadka je bila srednja AUC0-12 ur mikofenolne kisline primerljiva s tisto pri bolnikih brez zapoznelega delovanja ledvičnega presadka.
This will make sure that the bottle adapter and child safety bottle cap are in the right position.
• Tako bosta nastavek za steklenico in za otroke varna zaporka pravilno nameščena.
The types of adverse reactions reported during post-marketing with CellCept are similar to those seen in the controlled renal, cardiac and hepatic transplant studies.
Neželeni učinki, o katerih so poročali po prihodu zdravila CellCept na trg, so podobni tistim, ki so jih opazili v kontroliranih študijah pri presaditvah ledvic, srca in jeter.
Table 1 Summary of adverse drug reactions occurring in patients treated with CellCept reported from clinical trials and post marketing experience
Povzetek neželenih učinkov, ki so se pojavili pri bolnikih, zdravljenih z zdravilom CellCept in o katerih so poročali v kliničnih preskušanjih in po prihodu zdravila na trg
Lung problems such as:
Težave s sečili, kot so:
If you forget to take CellCept
Če ste pozabili vzeti zdravilo CellCept
Therefore, care should be taken if CellCept 1 g/5 ml powder for oral suspension is administered to patients with phenylketonuria (see section 6.1)
Pri dajanju zdravila CellCept 1 g/5 ml prašek za peroralno suspenzijo bolnikom s fenilketonurijo je zato potrebna previdnost (glejte poglavje 6.1).
Changes to CellCept therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimise the risk of graft rejection (see section 4.8).
Pri bolnikih s presadki se za zmanjšanje tveganja za zavrnitev presadka spremembe v zdravljenju z zdravilom CellCept lahko uvaja le pod ustreznim nadzorom (glejte poglavje 4.8).
The recommended dose of mycophenolate mofetil is 600 mg/m2 administered orally twice daily (up to a maximum of 2 g daily).
Priporočeni odmerek mofetilmikofenolata je 600 mg/m2, peroralno dvakrat na dan (do največ 2 g na dan).
Urinary problems such as: blood in the urine.
• kri v urinu.
Gastrointestinal disorders Abdominal distension
Bolezni prebavil abdominalna distenzija
Oral CellCept 1 g/5 ml powder for oral suspension should be initiated within 72 hours following transplantation.
Peroralno dajanje zdravila CellCept 1 g/5 ml prašek za peroralno suspenzijo je treba uvesti v 72 urah po presaditvi.
Write the expiry date of the made-up medicine on the bottle label.
Na nalepko steklenice napišite datum uporabnosti pripravljenega zdravila.
• The other ingredients are sorbitol, colloidal anhydrous silica, sodium citrate, soybean lecithin, mixed fruit flavour, xanthan gum, aspartame* (E951), methyl parahydroxybenzoate (E218), citric acid anhydrous.
• Pomožne snovi so: sorbitol, brezvoden koloidni silicijev dioksid, natrijev citrat, sojin lecitin, mešana sadna aroma, ksantanski gumi, aspartam* (E951), metilparahidroksibenzoat (E218), brezvodna citronska kislina.
Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, CellCept is contraindicated in nursing mothers (see section 4.3).
Zaradi možnih resnih škodljivih vplivov mofetilmikofenolata na dojenčke, je zdravilo CellCept pri doječih materah kontraindicirano (glejte poglavje 4.3).
Due to the large differences observed in the frequency of certain ADRs across the different transplant indications, the frequency is presented separately for renal, hepatic and cardiac transplant patients.
Zaradi velikih razlik v pogostnosti nekaterih neželenih učinkov pri uporabi za različne indikacije je pogostnost prikazana ločeno za bolnike z ledvičnim, jetrnim in srčnim presadkom.
The types of adverse reactions reported during post-marketing with CellCept are similar to those seen in the controlled renal and hepatic transplant studies.
Neželeni učinki, o katerih so poročali po prihodu zdravila CellCept na trg, so podobni tistim, ki so jih opazili v kontroliranih študijah pri presaditvah ledvic in jeter.
The initial dose of CellCept 500 mg powder for concentrate for solution for infusion should be given within 24 hours following transplantation.
Začetni odmerek zdravila CellCept 500 mg prašek za koncentrat za raztopino za infundiranje je treba dati v 24 urah po presaditvi.
OTHER SPECIAL WARNING(S), IF NECESSARY Avoid skin contact with infusion solution
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Izogibajte se neposrednemu stiku raztopine za infundiranje s kožo
• CellCept should not be given to women who are breastfeeding (see section 4.6).
• Zdravila CellCept ne smemo uporabljati pri bolnicah, ki dojijo (glejte poglavje 4.6).
No effects on fertility or reproductive parameters were evident in the dams or in the subsequent generation.
Pri samicah in nadaljnjih generacijah potomcev niso opazili učinkov na sposobnost razmnoževanja ali fertilnost.
• You are post-menopausal, i.e. at least 50 years old and your last period was more than a year ago (if your periods have stopped because you have had treatment for cancer, then there is still a chance you could become pregnant)
• ste v postmenopavzi, torej stari vsaj 50 let in ste imeli zadnjo menstruacijo pred več kot 1 letom
CellCept has a moderate influence on your ability to drive or use any tools or machines.
Zdravilo CellCept ima zmeren vpliv na sposobnost vožnje, upravljanja z orodji ali upravljanja strojev.
The adverse drug reactions (ADRs) from clinical trials and post marketing experience are listed in Table 1, by MedDRA system organ class (SOC) along with their frequencies.
Neželeni učinki iz kliničnih preskušanj in po prihodu zdravila na trg so navedeni v preglednici 1 po organskih sistemih MedDRA in po pogostnosti.
If you need to do it yourself, follow the steps below:
Če ga morate pripraviti sami, sledite spodnjim navodilom: Izogibajte se vdihavanju suhega praška.
Holding onto the body of the dispenser, carefully pull the dispenser out of the bottle adapter.
• Držite razdelilnik in previdno odstranite razdelilnik iz nastavka za steklenico.
Concomitant administration of telmisartan and CellCept resulted in an approximately 30% decrease of MPA concentrations.
Ob sočasnem jemanju telmisartana in zdravila CellCept se je koncentracija mikofenolne kisline zmanjšala za približno 30 %.
Add approximately half of the total amount of purified water to the bottle and shake the closed bottle well for about 1 minute.
Polovico prečiščene vode dodajte v steklenico in zaprto steklenico temeljito stresajte približno 1
This means that to prepare a 1 g dose of mycophenolate mofetil the content of 2 reconstituted vials (approx. 2 x 15 mL) must be further diluted into 140 mL glucose intravenous infusion 5% solution.
To pomeni, da za pripravo 1 g odmerka mofetilmikofenolata vsebino 2 raztopljenih vial (približno 2 x 15 ml) razredčimo še v 140 ml 5-% raztopine glukoze za intravensko infundiranje.